| Description | Obefazimod (ABX-464) is a potent anti-HIV agent. ABX464 inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) (IC50 : 0.1 μM - 0.5 μM) |
| In vivo | ABX464属于一类具有独特属性的抗HIV新分子。在人源化小鼠中，ABX464展现出长期效果，并能中和感染免疫细胞（包括储藏库）中HIV-1前病毒基因组的表达，因此被视为HIV功能性治愈的候选化合物[1]。 |
| Target activity | HIV-1:0.1 μM - 0.5 μM |
| Synonyms | ABX-464, ABX464 |
| molecular weight | 338.71 |
| Molecular formula | C16H10ClF3N2O |
| CAS | 1258453-75-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (295.24 mM) |
| References | 1. Campos N, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology. 2015 Apr 9;12:30. 2. Didier S , Regine R , Noel B P , et al. Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects[J]. Journal of Antimicrobial Chemotherapy(3):3. |